Drug General Information
Drug ID	D0M7CB
Former ID	DIB014984
Drug Name	MK-0873
Synonyms	MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co
Drug Type	Small molecular drug
Indication	Psoriasis [ICD9: 696; ICD10:L40]		Phase 2	[521664]
Company	Merck & Co Inc
Structure		Download 2D MOL 3D MOL
Formula	C25H18N4O3
Canonical SMILES	c1cc2c(n(cc(c2=O)C(=O)NC2CC2)c2cccc(c2)C#Cc2c[n+](ccc2)<br />[O-])nc1
PubChem Compound ID	9919680
Target and Pathway
Target(s)	CAMP-specific 3',5'-cyclic phosphodiesterase 4A	Target Info	Inhibitor	[529356]
	CAMP-specific 3',5'-cyclic phosphodiesterase 4B	Target Info	Inhibitor	[529356]
	Type IV phosphodiesterase	Target Info	Inhibitor	[529356]
KEGG Pathway	Purine metabolism
	cAMP signaling pathway
	Morphine addictionhsa00230:Purine metabolism
	Morphine addiction
NetPath Pathway	IL5 Signaling Pathway
	IL2 Signaling Pathway
PathWhiz Pathway	Purine Metabolism
Reactome	DARPP-32 events
	G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
	G alpha (s) signalling events
WikiPathways	G Protein Signaling PathwaysWP35:G Protein Signaling Pathways
	Myometrial Relaxation and Contraction Pathways
	Nuclear Receptors Meta-Pathway
	Opioid SignallingWP35:G Protein Signaling Pathways
	TSH signaling pathway
References
Ref 521664	ClinicalTrials.gov (NCT00132730) An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005). U.S. National Institutes of Health.
Ref 529356	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.